FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208201414> ?p ?o ?g. }

• W3208201414 endingPage "e2131749" @default.
• W3208201414 startingPage "e2131749" @default.
• W3208201414 abstract "Adults receiving dialysis treatment have a higher likelihood of death when infected with SARS-CoV-2 than adults not receiving dialysis treatment. To date, the immune response of people receiving dialysis after SARS-CoV-2 vaccination has not been systematically discussed.To assess immunogenicity rates in people with end-stage kidney disease (ESKD) receiving SARS-CoV-2 vaccines, explore postvaccination potential risk factors for nonresponse, and assess whether receiving dialysis is associated with different antibody response rates compared with the nondialysis population.This systematic review and meta-analysis used articles from PubMed, Medline, and Embase published before July 30, 2021, as well as articles in the medRxiv preprint server.Studies that evaluated the immunogenicity rate according to the postvaccine antibody response rate in patients with ESKD receiving dialysis were selected.The meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. A random-effects model was used. Two independent reviewers conducted the literature search and extracted the data.The primary outcome was the pooled antibody postvaccine response rates in individuals with ESKD. The secondary outcomes were pooled response rates in individuals receiving and not receiving dialysis. Subgroup analysis and meta-regression were conducted to identify the sources of heterogeneity.A total of 32 studies were included. The overall immunogenicity rate of the dialysis group was 86% (95% CI, 81%-89%). Meta-regression showed a significant difference was detected in the postvaccine response rate on the basis of prevalence of diabetes (regression coefficient, -0.06; 95% CI, -0.10 to -0.02; P = .004). Compared with nondialysis controls, patients in the dialysis group had a lower response rate after the first (relative risk [RR], 0.61; 95% CI, 0.47-0.79; I2 = 70.2%) and second (RR, 0.88; 95% CI, 0.82-0.93; I2 = 72.2%) doses, with statistically significantly increased RR between first and second doses (P = .007).These findings suggest that the immunogenicity rate among patients receiving dialysis was 41% after the first dose and 89% after the second dose. Diabetes might be a risk factor for nonresponse in the dialysis population. Patients receiving dialysis had a poorer antibody response rate than did individuals not receiving dialysis, particularly after the first dose." @default.
• W3208201414 created "2021-11-08" @default.
• W3208201414 creator A5001538242 @default.
• W3208201414 creator A5002421338 @default.
• W3208201414 creator A5006288322 @default.
• W3208201414 creator A5006475398 @default.
• W3208201414 creator A5010251523 @default.
• W3208201414 creator A5031898190 @default.
• W3208201414 date "2021-10-28" @default.
• W3208201414 modified "2023-10-18" @default.
• W3208201414 title "Immunogenicity Rates After SARS-CoV-2 Vaccination in People With End-stage Kidney Disease" @default.
• W3208201414 cites W2047526758 @default.
• W3208201414 cites W2069399184 @default.
• W3208201414 cites W2626109216 @default.
• W3208201414 cites W2790503929 @default.
• W3208201414 cites W2982433977 @default.
• W3208201414 cites W2986205132 @default.
• W3208201414 cites W3031784966 @default.
• W3208201414 cites W3048702451 @default.
• W3208201414 cites W3094590767 @default.
• W3208201414 cites W3128949192 @default.
• W3208201414 cites W3136355231 @default.
• W3208201414 cites W3150786652 @default.
• W3208201414 cites W3153923596 @default.
• W3208201414 cites W3154170850 @default.
• W3208201414 cites W3154739456 @default.
• W3208201414 cites W3154963136 @default.
• W3208201414 cites W3155040466 @default.
• W3208201414 cites W3155408150 @default.
• W3208201414 cites W3156422980 @default.
• W3208201414 cites W3157252954 @default.
• W3208201414 cites W3162345172 @default.
• W3208201414 cites W3162719213 @default.
• W3208201414 cites W3163037703 @default.
• W3208201414 cites W3163998267 @default.
• W3208201414 cites W3164119498 @default.
• W3208201414 cites W3164209947 @default.
• W3208201414 cites W3165288307 @default.
• W3208201414 cites W3165367963 @default.
• W3208201414 cites W3165626023 @default.
• W3208201414 cites W3165694484 @default.
• W3208201414 cites W3165884098 @default.
• W3208201414 cites W3166184636 @default.
• W3208201414 cites W3166460483 @default.
• W3208201414 cites W3167220489 @default.
• W3208201414 cites W3168042374 @default.
• W3208201414 cites W3170537423 @default.
• W3208201414 cites W3171119261 @default.
• W3208201414 cites W3172450091 @default.
• W3208201414 cites W3176527986 @default.
• W3208201414 cites W3177491663 @default.
• W3208201414 cites W3179977392 @default.
• W3208201414 cites W3183775993 @default.
• W3208201414 cites W3184968462 @default.
• W3208201414 cites W3186556643 @default.
• W3208201414 cites W3189028477 @default.
• W3208201414 cites W3192494915 @default.
• W3208201414 cites W3192631736 @default.
• W3208201414 cites W3216599998 @default.
• W3208201414 cites W4200536436 @default.
• W3208201414 doi "https://doi.org/10.1001/jamanetworkopen.2021.31749" @default.
• W3208201414 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8554642" @default.
• W3208201414 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34709385" @default.
• W3208201414 hasPublicationYear "2021" @default.
• W3208201414 type Work @default.
• W3208201414 sameAs 3208201414 @default.
• W3208201414 citedByCount "51" @default.
• W3208201414 countsByYear W32082014142021 @default.
• W3208201414 countsByYear W32082014142022 @default.
• W3208201414 countsByYear W32082014142023 @default.
• W3208201414 crossrefType "journal-article" @default.
• W3208201414 hasAuthorship W3208201414A5001538242 @default.
• W3208201414 hasAuthorship W3208201414A5002421338 @default.
• W3208201414 hasAuthorship W3208201414A5006288322 @default.
• W3208201414 hasAuthorship W3208201414A5006475398 @default.
• W3208201414 hasAuthorship W3208201414A5010251523 @default.
• W3208201414 hasAuthorship W3208201414A5031898190 @default.
• W3208201414 hasBestOaLocation W32082014141 @default.
• W3208201414 hasConcept C124936440 @default.
• W3208201414 hasConcept C126322002 @default.
• W3208201414 hasConcept C203014093 @default.
• W3208201414 hasConcept C22070199 @default.
• W3208201414 hasConcept C2779134260 @default.
• W3208201414 hasConcept C2779978075 @default.
• W3208201414 hasConcept C2780868878 @default.
• W3208201414 hasConcept C2908647359 @default.
• W3208201414 hasConcept C3019040382 @default.
• W3208201414 hasConcept C71924100 @default.
• W3208201414 hasConcept C8891405 @default.
• W3208201414 hasConcept C95190672 @default.
• W3208201414 hasConcept C99454951 @default.
• W3208201414 hasConceptScore W3208201414C124936440 @default.
• W3208201414 hasConceptScore W3208201414C126322002 @default.
• W3208201414 hasConceptScore W3208201414C203014093 @default.
• W3208201414 hasConceptScore W3208201414C22070199 @default.
• W3208201414 hasConceptScore W3208201414C2779134260 @default.
• W3208201414 hasConceptScore W3208201414C2779978075 @default.
• W3208201414 hasConceptScore W3208201414C2780868878 @default.

• next